AFICAMTEN - Generic Drug Details

What are the generic sources for aficamten and what is the scope of freedom to operate?

Aficamten is the generic ingredient in one branded drug marketed by Cytokinetics and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for AFICAMTEN

International Patents:	74
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	7
Patent Applications:	46
What excipients (inactive ingredients) are in AFICAMTEN?	AFICAMTEN excipients list
DailyMed Link:	AFICAMTEN at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AFICAMTEN

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AFICAMTEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bayer	PHASE3
Cytokinetics	PHASE2
Cytokinetics	Phase 1

See all AFICAMTEN clinical trials

US Patents and Regulatory Information for AFICAMTEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cytokinetics	MYQORZO	aficamten	TABLET;ORAL	219083-001	Dec 19, 2025		RX	Yes	Yes			Y	Y
Cytokinetics	MYQORZO	aficamten	TABLET;ORAL	219083-003	Dec 19, 2025		RX	Yes	No
Cytokinetics	MYQORZO	aficamten	TABLET;ORAL	219083-004	Dec 19, 2025		RX	Yes	No			Y	Y

International Patents for AFICAMTEN

Country	Patent Number	Title	Estimated Expiration
Argentina	114182
Australia	2019208331
Australia	2024204859

Aficamten Market Dynamics and Financial Trajectory

Last updated: August 28, 2026

Aficamten is Cytokinetics' next-generation cardiac myosin inhibitor for hypertrophic cardiomyopathy. Its commercial case depends on competing with Bristol Myers Squibb's Camzyos (mavacamten), reducing monitoring and drug-interaction burdens, and converting positive Phase 3 data into regulatory approvals. As of June 2024, aficamten had no FDA approval, no commercial revenue, no Orange Book listing, and no approved-product exclusivity. Its value was concentrated in clinical differentiation, regulatory execution, and Cytokinetics' ability to finance a launch.

What is aficamten and which market does it target?

Aficamten, formerly CK-274, is an oral, selective cardiac myosin inhibitor designed to reduce excessive actin-myosin interaction in hypertrophic cardiomyopathy, or HCM. Cytokinetics is developing it for symptomatic obstructive HCM and potentially nonobstructive HCM.

HCM is a chronic cardiac disease characterized by abnormal thickening of the heart muscle. Drug treatment historically relied on beta blockers, calcium-channel blockers and disopyramide. Cardiac myosin inhibitors created a new disease-modifying category by reducing excessive contractility.

The initial commercial market is obstructive HCM, where patients have left ventricular outflow tract obstruction and substantial symptom burden. Cytokinetics has also tested aficamten in nonobstructive HCM, which could materially expand the addressable population if regulators accept the evidence.

Item	Aficamten position
Developer	Cytokinetics, Inc.
Former development code	CK-274
Drug class	Cardiac myosin inhibitor
Initial target	Symptomatic obstructive HCM
Expansion opportunity	Nonobstructive HCM
Route	Oral
FDA status as of June 2024	Not approved
Commercial revenue as of June 2024	None attributable to aficamten
Principal competitor	Camzyos, mavacamten
Major clinical program	SEQUOIA-HCM

Cytokinetics reported that SEQUOIA-HCM met its primary endpoint, demonstrating improvement in peak oxygen uptake and cardiac structure in patients with obstructive HCM. The company also reported positive results from FOREST-HCM, REDWOOD-HCM and other supportive studies.[1][2]

When could aficamten lose regulatory exclusivity?

Aficamten had not reached FDA approval as of June 2024, so no statutory FDA approval date, new chemical entity exclusivity period or patent-term-adjusted expiry date had been established.

The likely U.S. exclusivity sequence is:

Milestone	Status as of June 2024
Investigational development	Active
Breakthrough Therapy designation	Granted by FDA in 2021
New drug application	Not publicly approved or commercially launched
FDA approval	Pending
Five-year NCE exclusivity	Not yet started
Three-year clinical-investigation exclusivity	Not yet started
Orange Book listing	None for an approved aficamten product
Generic Paragraph IV litigation	None tied to an approved aficamten product
Patent-term extension	Not yet determinable

If approved as a new chemical entity, aficamten could receive five years of FDA data exclusivity under the Federal Food, Drug, and Cosmetic Act. A generic could not file an ANDA during the first four years unless it submitted a Paragraph IV certification. Patent-term extension, if granted, could add up to five years to an eligible patent, subject to statutory limits.[3]

The practical loss-of-exclusivity date will depend on four factors:

1. The earliest enforceable composition-of-matter patent.
2. Any patent-term adjustment or extension.
3. FDA approval timing.
4. The scope of formulation, dosing and method-of-use patents.

What patents protect aficamten?

Aficamten's patent protection is expected to include composition-of-matter claims, pharmaceutical compositions, therapeutic methods, dosing regimens and manufacturing processes. The commercial value is likely concentrated in composition claims and claims directed to maintaining cardiac function while reducing obstruction.

Publicly available patent records indicate a Cytokinetics-centered patent estate covering cardiac myosin inhibitors and related uses. Exact expiration dates vary by family, jurisdiction and patent-term adjustment. The core patent analysis must distinguish between:

Patent category	Commercial purpose	Expected importance
Composition of matter	Protects aficamten and structurally related compounds	Highest
Pharmaceutical composition	Protects dosage forms and excipients	Moderate
Method of treatment	Protects use in obstructive or nonobstructive HCM	Moderate to high
Dosing regimen	Protects titration, monitoring or dose-selection methods	Moderate
Manufacturing process	Raises production and scale-up barriers	Low to moderate unless difficult to design around
Combination therapy	May cover use with standard HCM treatments	Selective

Because aficamten was not approved as of June 2024, FDA's Orange Book did not provide an approved-product patent list. The relevant patent estate therefore had to be assessed through USPTO, WIPO and national patent records rather than through an Orange Book certification analysis.[4][5]

Aficamten's patent strength is potentially higher than its regulatory exclusivity profile because the underlying molecule was discovered and developed specifically for the cardiac myosin mechanism. Generic competition would need to address both composition patents and clinical-use patents. Patent durability remains dependent on claim scope and validity, not simply on the number of patent families.

How does aficamten compare with Camzyos?

Camzyos is the only approved cardiac myosin inhibitor in the United States as of June 2024. It gives Bristol Myers Squibb first-mover advantages, including established prescriber familiarity, reimbursement precedent and real-world safety experience. Aficamten's commercial strategy is based on reducing Camzyos' operational constraints.

Attribute	Aficamten	Camzyos
Developer	Cytokinetics	Bristol Myers Squibb
Active ingredient	Aficamten	Mavacamten
U.S. approval as of June 2024	No	Yes
FDA approval date	Not applicable as of cutoff	April 28, 2022
Indication	In development for symptomatic obstructive HCM	Adults with symptomatic NYHA class II-III obstructive HCM
REMS	Expected to require risk controls if approved	Required
Key safety concern	Reduced ejection fraction	Reduced ejection fraction and heart failure
Half-life profile	Shorter than mavacamten based on development disclosures	Approximately 6 to 9 days
Dose adjustment	Designed for more predictable titration	Requires echocardiographic monitoring and dose management
Commercial advantage	Potentially simpler treatment management	Established market access and launch infrastructure
Commercial disadvantage	No approval or sales history as of cutoff	First-mover position

The shorter pharmacokinetic profile is central to aficamten's positioning. Cytokinetics has argued that aficamten may permit faster dose adjustment and recovery after treatment interruption than mavacamten. That advantage could matter to physicians treating patients with fluctuating ventricular function, but it must translate into labeling, monitoring requirements and payer value.

Camzyos is subject to a Risk Evaluation and Mitigation Strategy, or REMS, because excessive reduction in cardiac contractility can cause heart failure. Aficamten would likely face comparable regulatory scrutiny. A shorter half-life could reduce the duration of risk after a dose change, but it does not eliminate the need for cardiac monitoring.[6]

What clinical results support aficamten's market opportunity?

SEQUOIA-HCM was the principal registration-enabling study in obstructive HCM. Cytokinetics reported that aficamten improved exercise capacity and reduced measures of cardiac obstruction compared with placebo.

Key clinical signals reported by the company included:

• Improvement in peak oxygen uptake.
• Reduction in left ventricular outflow tract gradients.
• Improvement in New York Heart Association functional class.
• Reduction in disease-related cardiac remodeling measures.
• Low rates of severe systolic dysfunction in the reported study population.

REDWOOD-HCM evaluated aficamten in patients receiving background therapy and generated data on obstruction reduction and ventricular function. FOREST-HCM supplied longer-term extension data. SEQUOIA-HCM-CMS examined patients with obstructive HCM who were eligible for septal reduction therapy, supporting the possibility that medical treatment could delay or reduce procedural intervention in some patients.[1][2]

The commercial interpretation is narrower than a claim that aficamten replaces surgery. The drug's value is more likely to come from:

• Treating patients before referral for septal reduction.
• Offering an alternative to patients who are poor procedural candidates.
• Expanding treatment among patients who are undertreated because of symptom burden or treatment complexity.
• Capturing patients who discontinue or avoid Camzyos because of monitoring or interaction concerns.

What is the FDA regulatory status of aficamten?

As of June 2024, aficamten had FDA Breakthrough Therapy designation but had not received marketing approval. Breakthrough designation can accelerate development and regulatory interaction, but it does not guarantee approval or eliminate requirements for adequate safety and efficacy evidence.

The main FDA review risks are:

Risk of reduced ejection fraction

Cardiac myosin inhibition can cause excessive reduction in contractility. The FDA will assess the frequency, reversibility and clinical consequences of reduced ejection fraction, including events requiring treatment interruption.

Monitoring and REMS burden

If approved, aficamten may require echocardiography and a restricted distribution or monitoring program. A less burdensome program than Camzyos would create a meaningful commercial advantage. A similar program would weaken the differentiation.

Label scope

An approval limited to symptomatic obstructive HCM would produce a focused initial market. A label that includes broader patient groups, including nonobstructive HCM or patients receiving certain background treatments, would increase commercial potential.

Drug interactions

Mavacamten has clinically important interactions with CYP2C19 and CYP3A4 modulators. Aficamten's interaction profile could affect prescribing convenience and patient eligibility. The final label, not early development data, will determine the magnitude of this advantage.

How large is the aficamten revenue opportunity?

Aficamten had no product revenue as of June 2024. Its near-term financial trajectory was therefore driven by research spending, regulatory costs, financing activity and business-development transactions rather than sales.

The commercial opportunity can be modeled through treated-patient penetration rather than total HCM prevalence:

Revenue driver	Positive case	Downside case
Approval	Broad obstructive HCM label	Narrow label or delayed approval
Price	Specialty-drug pricing consistent with rare cardiovascular therapy	Payer discounts and restrictive authorization
Patient uptake	Differentiation on monitoring and tolerability	Camzyos retains prescriber and payer control
Duration	Chronic use with high persistence	Discontinuation from safety, cost or monitoring
Market expansion	Nonobstructive HCM and earlier-line use	No label expansion
Competition	Limited near-term competition	Camzyos price response and future entrants

Cytokinetics' financial exposure was high because aficamten was its leading late-stage asset. The company had to fund Phase 3 completion, regulatory submissions, commercial preparation and post-approval studies before receiving product revenue. That creates a funding gap: operating cash outflows rise before sales begin.

Potential value inflection points included:

1. Completion of the registration package.
2. FDA acceptance of the NDA.
3. Approval and label language.
4. REMS requirements.
5. Launch pricing and payer coverage.
6. Early prescription growth and persistence.
7. Evidence supporting nonobstructive HCM expansion.
8. Licensing or co-commercialization arrangements.

Which companies are competing with aficamten?

Bristol Myers Squibb is the direct commercial competitor through Camzyos. Other competition comes from established HCM medicines, septal reduction procedures and future cardiac myosin inhibitors.

Competitor or substitute	Competitive effect
Camzyos	Direct mechanism and indication competitor
Beta blockers	Low-cost first-line symptomatic treatment
Verapamil and diltiazem	Alternative rate and symptom management
Disopyramide	Used in selected obstructive patients
Septal myectomy	Durable procedural treatment
Alcohol septal ablation	Less invasive procedural option
Future myosin inhibitors	Potential follow-on competition

Aficamten's strongest differentiation would be a combination of efficacy, manageable safety, rapid dose reversibility and lower administrative burden. A marginal efficacy advantage alone may not overcome Camzyos' established position.

What licensing deals affect aficamten?

As of June 2024, Cytokinetics retained the central development and commercialization position for aficamten. The company had entered major strategic transactions involving other assets, including a collaboration with Amgen relating to omecamtiv mecarbil, but that transaction did not establish a disclosed aficamten commercial partner.[7]

Aficamten could attract a licensing or co-commercialization partner because:

• Cytokinetics had limited commercial infrastructure compared with Bristol Myers Squibb.
• The drug required specialist cardiology access and monitoring.
• Global commercialization would require country-specific pricing and reimbursement capabilities.
• A partner could reduce launch financing requirements.

The trade-off is dilution of economics. A global partnership could provide upfront cash, milestone payments and sales support while reducing Cytokinetics' share of future revenue.

What generic entry risks exist for aficamten?

Generic entry before the core composition patent expires is unlikely if the principal claims survive validity challenges. The most credible early challenges would target:

• Obviousness of the claimed compound.
• Written-description or enablement issues.
• Lack of novelty in prior cardiac myosin inhibitor disclosures.
• Narrow or vulnerable method-of-use claims.
• Design-around opportunities using alternative salts, polymorphs or formulations.

A Paragraph IV challenge cannot produce immediate generic entry if enforceable patents remain in force. It can trigger patent litigation and a potential 30-month stay after the NDA holder receives notice, subject to statutory conditions.[3]

The more important medium-term risk may come from label-driven competition rather than a traditional generic. A rival could seek approval for a different cardiac myosin inhibitor, a different formulation or a competing indication. Patent protection over aficamten's molecule would not block all competing mechanisms.

How strong is the aficamten patent estate?

Aficamten's patent estate appears commercially meaningful because protection can extend across the molecule, therapeutic use and dose-management architecture. Its effective strength depends on whether the core composition claims remain enforceable and whether later-filed patents provide meaningful additional term.

Strength factor	Assessment
Core molecule protection	Potentially strong if broad composition claims survive
Formulation protection	Relevant but usually more design-aroundable
Method-of-use protection	Valuable for labeled HCM indications
Dosing patents	Can protect clinical differentiation but face validity risk
Manufacturing patents	Relevant if production is technically complex
Orange Book leverage	Not available before approval
Litigation visibility	Limited before an ANDA is filed
Geographic coverage	Dependent on national prosecution and granted claims

The estate should be valued by enforceable claim coverage and remaining term, not by raw patent count. U.S. protection is commercially central, but European, Japanese and other major-market rights will determine the global launch profile.

Key Takeaways

• Aficamten was a precommercial, late-stage cardiac myosin inhibitor as of June 2024.
• Cytokinetics' principal commercial thesis was improved titration and reversibility compared with Camzyos.
• Camzyos had the first-mover advantage, FDA approval, prescriber familiarity and reimbursement infrastructure.
• Aficamten had no FDA approval, Orange Book listing, product revenue or established FDA exclusivity period as of the cutoff.
• The principal regulatory risk was reduced ejection fraction and the resulting monitoring or REMS burden.
• The patent estate is likely to rely on composition, method-of-treatment, dosing and formulation claims.
• Financial risk was concentrated in prelaunch spending and the need to finance commercialization before revenue generation.
• The most important value inflection points were FDA approval, label scope, REMS design, payer coverage and launch uptake.
• Nonobstructive HCM could materially expand the opportunity, but that expansion depended on regulatory and clinical evidence.
• An early licensing deal could improve funding capacity while reducing Cytokinetics' retained economics.

FAQs About Aficamten Market and Financial Outlook

Is aficamten approved by the FDA?

No. As of June 2024, aficamten had FDA Breakthrough Therapy designation but had not received FDA marketing approval.

Will aficamten replace Camzyos?

No conclusion can be made before approval and commercial launch. Aficamten was designed to compete through pharmacokinetic and monitoring advantages, while Camzyos had first-mover and market-access advantages.

Does aficamten have an Orange Book patent listing?

No approved aficamten product and no related Orange Book listing existed as of June 2024.

What could make aficamten commercially unsuccessful?

The main risks were a narrow FDA label, stringent REMS requirements, safety-related treatment interruptions, weak payer coverage, slower physician adoption and competition from Camzyos or later cardiac myosin inhibitors.

Could aficamten become a multibillion-dollar drug?

That outcome would require broad patient uptake in obstructive HCM, strong persistence, favorable reimbursement, effective differentiation from Camzyos and successful expansion into nonobstructive HCM or other cardiac indications.

References

1. Cytokinetics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.

2. Cytokinetics, Inc. (2024). Aficamten clinical development program and SEQUOIA-HCM results. Investor and corporate presentations.

3. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug application patent certifications. FDA.

4. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System. USPTO.

5. World Intellectual Property Organization. (2024). PATENTSCOPE database. WIPO.

6. U.S. Food and Drug Administration. (2022). Camzyos prescribing information and Risk Evaluation and Mitigation Strategy. FDA.

7. Amgen Inc. (2023). Annual report for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.